Tokyo-based Astellas Pharma Inc. will present its latest findings on acute myeloid leukemia (AML) during the 2017 American Society of Hematology Annual Meeting.
The American Society of Hematology's 59th yearly summit is slated for Dec. 9-12 at the Georgia World Congress Center in Atlanta.
Participants representing Astellas will elaborate on preliminary results from a Phase 1 study of gilteritinib, an investigational agent, in combination with induction and consolidation chemotherapy in newly diagnosed AML patients, according to a company announcement.
"This research further shows FLT3 mutations are one of the most commonly occurring mutations in AML, and we are pleased to be continuing our commitment to addressing the needs of AML patients," Dr. Steven Benner, senior vice president and global therapeutic area head of Astellas’ oncology development, said in the announcement. "Further, we're pleased to showcase additional data that examines the cost of care as well as healthcare utilization in the current treatment of FLT3mut+ AML."
Dr. Keith Pratz of John Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore will present “Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-mut and FLT3-wt Acute Myeloid Leukemia: A Multi-country Medical Chart Study," the announcement said.
In addition to Pratz’ presentation, Astellas will display several abstracts during the event's poster sessions.
